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ABSTRACT 
 
OBJECTIVE: The objective of this selective EBM review is to determine whether or not the use 
of TENS is safe and effective in preventing and treating PHN. 
 
STUDY DESIGN: Two randomized controlled trials and one retrospective observational study 
that were published in peer-reviewed journals after 2006 in the English language were reviewed. 
 
DATA SOURCES: Studies were found in the PubMed database and selected based on relevance 
to the research question and whether they evaluated patient oriented outcomes. 
 
OUTCOMES MEASURED: Prevention of PHN, determined by absence or presence of 
symptoms, and reduction of pain due to PHN, using a visual analog scale (VAS). 
 
RESULTS: In the first RCT, Barbarisi et al showed that TENS therapy along with pregabalin 
caused a statistically significant reduction in pain (p < 0.02) compared to pregabalin plus placebo 
device. Stepanovic et al studied the use of TENS in preventing PHN and found that it was 
significantly better than antiviral treatment (p = 0.001). In the retrospective observational study 
by Kolsek, 0% of patients treated with TENS therapy during acute HZ developed PHN, 
compared to 28.6% of patients treated with antivirals. 
 
CONCLUSIONS: The use of TENS is both safe and effective in preventing and treating 
postherpetic neuralgia. 
 
KEYWORDS: transcutaneous electrical nerve stimulation, postherpetic neuralgia 
 
 
Suzenski | TENS and Postherpetic Neuralgia | 1 
INTRODUCTION 
Herpes Zoster (HZ) is a dermatologic condition caused by the reactivation of Varicella 
Zoster Virus (VZV). It affects approximately 30% of the population, leading to 1 million new 
cases diagnosed each year1. The virus remains dormant in dorsal root ganglia following varicella 
infection, and is believed to reactivate due to reduced cellular immunity associated with 
immunocompromising states such as stress and increased age2. HZ is a clinical diagnosis 
characterized by a vesicular eruption in a dermatomal distribution, most commonly on the trunk. 
It is a self-limiting, viral infection lasting up to a few weeks with relatively low incidences of 
morbidity and mortality. Up to 30% of patients, however, go on to develop post-herpetic 
neuralgia (PHN)3,4,5,6. 
PHN, the most common complication of HZ, is characterized by moderate to severe 
burning, tingling, and/or hyperesthesia in a dermatomal pattern that lasts months to years, and is 
occasionally lifelong. The pathophysiology of PHN is not completely understood but is believed 
to be multifactorial, involving the necrosis, fibrosis, and destruction of afferent nerve fibers to 
the spinal cord2. 
Many cases of HZ are treated with antivirals such as acyclovir, valacyclovir, and 
brivudine. Antiviral therapy has been shown to decrease severity and duration of HZ, but no 
treatment has been shown to decrease the incidence of PHN3,6. The current first line treatments 
for PHN are tricyclic antidepressants like amitriptyline, and anti-seizure drugs like gabapentin 
and pregabalin7. Topical agents such as capsaicin cream and lidocaine are also frequently used 
for more mild cases or patients that do not want systemic therapy. Although the use of opioids 
for chronic pain is controversial, their efficacy in treating PHN has been shown in a small 
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number of trials and these agents are still commonly prescribed7. Less commonly used methods 
for refractory pain include glucocorticoid injections and botulinum toxin injections7. 
The estimated annual health care cost of HZ in the United States is $1.1 billion8. Patients 
who go on to develop PHN have health care costs that are 4 - 7 times higher than patients who do 
not develop the complication, costing up to $11,147 per case9. The costs associated with HZ and 
subsequent PHN can partly be explained by the difficulty in treating neuropathic pain and the 
need for chronic treatment. 
While pharmacologic therapies remain the mainstay of treatment for PHN, these drugs 
are not always effective in reducing pain and create a challenge for physicians and patients. A 
non-pharmacologic intervention, transcutaneous electrical nerve stimulation (TENS), has been 
shown to effectively reduce pain in various acute and chronic conditions3,7,10. TENS is the 
process by which electrodes placed on the skin produce an electrical current that activates 
various receptors leading to pain reduction. This application has been shown to provide analgesia 
both peripherally and centrally by activating opioid, serotonin, muscarinic, and alpha-2 
noradrenergic receptors3,10. TENS may be safe and effective in decreasing pain caused by PHN, 
and possibly in preventing PHN altogether. 
With the aging population, the number of patients experiencing HZ is expected to 
increase, leading to an increased number of patients with PHN. New modalities of pain relief that 
are both safe and effective will become increasingly important for the PA profession, and 
providers as a whole, as the number of patients requiring treatment increases. 
OBJECTIVE 
The objective of this systematic review is to determine whether or not the use of TENS is 
safe and effective in treating and preventing PHN. 
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METHODS 
This paper evaluates two randomized controlled trials (RCTs) and one retrospective 
observational study. All three studies compared the use of TENS to a visually-matched placebo 
device, another traditional treatment modality, or no treatment. The primary outcomes measured 
were prevention of PHN and reduction of pain. Articles were searched through the PubMed 
database and selected based on relevance to the research question and whether or not patient-
oriented outcomes were used. Keywords used included “transcutaneous electrical nerve 
stimulation” and “postherpetic neuralgia”. Articles published in English in peer-reviewed 
journals after 2006 were evaluated. The demographics and specific characteristics of each study 
are represented in Table 1. 
 
Table 1. Demographics and characteristics of included studies. 
 
Study Type # Pts Age 
in 
years 
Inclusion Criteria Exclusion Criteria W/D Interventions 
Barbarisi, 
2010 
RCT 30 50-80 PHN > 3 mo; locations 
of pain at cervical, 
thoracic, lumbar, or 
sacral root ganglions; 
VAS score of at least 
60 mm 
Hypersensitivity to 
pregabalin; 
neoplastic, 
hematologic, hepatic, 
renal disease; 
immunodeficiency; 
occipital, trigeminal 
HZ; alcohol misuse 
w/in 2 y; serious 
psychological 
condition 
0 Pregabalin 
(300mg and 
600mg doses) 
+ TENS 
therapy  
Kolsek, 
2012 
Retrospective, 
observational 
102 68.9 
+/- 
16.6 
Patients in the 
electronic medical 
record of a health 
center in Slovenia 
with clinical diagnosis 
of HZ 
Patients that moved 
away whose later 
records could not be 
analyzed; patients 
that were 
hospitalized; patients 
with ocular 
involvement 
0 TENS therapy 
alone, 
antiviral 
therapy alone, 
TENS + 
antiviral 
Stepanovic, 
2016 
RCT 222 69 +/- 
17.31 
Patients in a primary 
health care office that 
Patients with HZ in 
the ocular or genital 
region; 
0 TENS therapy 
alone, 
antiviral 
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presented with clinical 
diagnosis of HZ 
immunocompromised 
patients, patients with 
chronic diseases; 
patients with previous 
neuropathic pain 
therapy alone, 
TENS + 
antiviral 
 
 
OUTCOMES MEASURED 
The primary outcomes measured in all three studies were prevention of PHN in patients 
with HZ and reduction of pain due to PHN. In the study by Barbarisi et al, the primary measure 
of reduction of pain due to PHN was a change in baseline of a visual analog scale (VAS), “0” 
being no pain and “100 mm” being worst possible pain. Over the four week experiment patients 
filled out the VAS for pain at each visit. The authors also measured sleep interference due to pain 
using a questionnaire that patients completed at each visit. Treatment groups for this study 
included use of pregabalin (300mg dose) + TENS therapy, pregabalin (600mg dose) + TENS 
therapy, and two groups with each respective dose of pregabalin + TENS placebo. 
In the study by Stepanovic et al, the primary outcome measured was prevention of PHN 
using TENS therapy. Patients with clinical diagnosis of HZ were treated either with TENS 
therapy alone, TENS + antiviral therapy, antiviral therapy alone, or no intervention. To 
determine incidence of PHN, the authors had patients record the presence or absence of the 
following symptoms over a 6 month period: spontaneous feelings of pain, allodynia, 
hyperalgesia, and/or paresthesia. The authors also analyzed adverse events between treatment 
groups. 
In the retrospective observational study by Kolsek, the primary outcome measured was 
prevention of PHN. The author evaluated this outcome using medical records of patients treated 
for HZ in three outpatient family practices. The treatment groups included TENS therapy alone, 
antiviral therapy alone, TENS + antiviral therapy, and the control group included patients who 
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received no therapy or who received any of the therapies but presented to treatment after 72 
hours of rash eruption. The author analyzed the use of analgesics among treatment groups, 
incidence of PHN, and adverse events related to any of the treatment types. 
RESULTS 
 The study by Barbarisi et al was a randomized, placebo-controlled trial that included 30 
patients receiving either pregabalin (300 or 600 mg) with TENS therapy or pregabalin (300 mg 
or 600 mg) with a visually matched TENS placebo device. The statistical analyses used by the 
authors include mean change in baseline and ANOVA. The patients receiving TENS therapy at 
either dose of pregabalin showed statistically significant reductions in pain compared to groups 
receiving respective doses of pregabalin and TENS placebo (p < 0.02 for both doses of 
pregabalin). The results of the study are shown in Table 2. Compliance to drug therapy was not 
reported, however compliance to TENS therapy was maintained as each patient received therapy 
on location at the test site. 
 
Table 2. Summary of reduction in pain from baseline from Barbarisi et al. 
Treatment Reduction in Pain from Baseline 
600 mg Pregabalin + TENS 40% 
600 mg Pregabalin + Placebo 16% 
300 mg Pregabalin + TENS 30% 
300 mg Pregabalin + Placebo 10% 
 
 
 In the RCT by Stepanovic et al, the authors evaluated the efficacy of TENS therapy, 
antivirals, TENS therapy + antivirals, or no treatment on the prevention of PHN. To determine 
the effect of each treatment group on development of PHN, they performed a logistic regression, 
using presence of PHN and treatment type as the dependent and independent variables, 
respectively. They reported a statistically significant correlation between the treatment types and 
PHN (p = 0.001); the odds for developing PHN were significantly lower in patients treated with 
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TENS therapy alone, with a numbers needed to treat (NNT) of 4. The odds of developing PHN 
using any of the other treatments were not statistically significant. The results of this study are 
summarized in Table 3. The authors report that the only adverse events of the trial were bacterial 
skin infections and no serious complications were reported. There was no statistical difference in 
adverse events between treatment groups (p = 0.128). Compliance to drug therapy was not noted, 
but TENS therapy was given on location at the test site to maintain compliance. 
 
Table 3. Summary of results of logistic regression on prediction of PHN using Odds Ratio (OR) 
from Stepanovic et al. 
Treatment OR (95% CI) p NNT 
TENS therapy 0.15 (0.05; 0.47) 0.001 4 
 
 The article by Kolsek was a retrospective observational study that examined the medical 
records of 102 patients treated for HZ in outpatient family practices. A Chi squared test was used 
to analyze differences in prevalence of PHN between treatment groups. The rate of patients with 
PHN in the TENS therapy group was 0%, the antiviral group was 28.6%, antiviral + TENS 
therapy group was 20.8%, and the control group without therapy had a rate of 14.3%. TENS 
therapy alone had the greatest statistically significant decrease in rate of PHN with p = 0.024. 
Using this data, 4 patients would need to be treated with TENS therapy in order to prevent 1 
patient from developing PHN (NNT=4), as compared to traditional antiviral therapy. The results 
of this study are summarized in Table 4. Adverse events were not reported numerically but the 
author claimed that the only complication included secondary bacterial infection and the 
difference between treatment groups was not significant. Compliance to drug therapy was not 
noted. The author also does not indicate whether TENS therapy was done in the office or at 
home, and again does not mention compliance. 
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Table 4. Summary of treatment effects of TENS therapy on preventing PHN from Kolsek study. 
Relative Risk Reduction (RRR) Absolute Risk Reduction (ARR) NNT 
0.4 28.6% 4 
 
 
DISCUSSION 
The treatment of PHN remains a difficult task for providers. Despite vaccination efforts, 
the incidence of HZ has increased within recent years, likely due to a shift in demographics and 
the aging population1. With increases in HZ occurrence, the number of patients developing PHN 
is going to increase, with older adults having the greatest chance of developing the 
complication3,4,5.  
TENS therapy has been shown to be effective in reducing acute and chronic pain in some 
studies, yet its use in certain conditions remains controversial and meta analyses on its efficacy 
continue to have conflicting results7,10,11. In the Barbarisi et al study analyzed in this systematic 
review, TENS therapy along with standard treatment methods was shown to significantly 
decrease pain due to PHN compared to standard treatment methods alone. These results may 
imply that multiple treatment modalities should be used when treating chronic pain. A 
shortcoming to this study was that the physician administering the TENS device or TENS 
placebo device was not blinded. The authors explain how blinding would be impossible as the 
administering physician needed to explain to patients that they would either experience an 
electrical tingling sensation or nothing at all. The sample size was also very small in this study, 
with each treatment group containing between 6 and 8 patients. It is also important to note that 
compliance to drug therapy was not reported in the study. 
While antivirals decrease the duration and intensity of HZ, they have no effect on the 
prevalence of PHN3,4. Vaccination has been shown to decrease incidence of HZ and therefore 
PHN6, but with the aging population the incidence of PHN continues to be up to 30%3. The use 
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of TENS therapy during HZ has been shown to decrease the incidence of PHN4,5,11. In this 
systematic review, two studies assessing the efficacy of TENS therapy in reducing PHN were 
analyzed. In the RCT by Stepanovic et al, TENS therapy alone was shown to have a significant 
decrease on the incidence of PHN, when compared to antiviral therapy given alone or in addition 
to TENS therapy. The pathophysiology behind the combination of antivirals and TENS therapy 
not reducing PHN is unknown and needs to be investigated further, but these findings are 
consistent with other trials4,11. The retrospective observational study by Kolsek showed that 
TENS therapy during HZ resulted in a 100% decrease in PHN incidence and was significantly 
better in preventing PHN than antivirals. The study has some limitations because it is 
retrospective and observational. One could speculate that patients receiving only TENS therapy 
had less severe cases of HZ, which has been linked to a decreased chance of developing PHN5,11. 
Another limitation with this study is that the placebo effect could have played a major role. 
Patients in the treatment group receiving TENS therapy all came from the same practicing 
physician who the author states had always used TENS to treat HZ. If that was a common 
practice by that physician, then it is likely that he would have told patients the device decreases 
pain and has been shown to be effective, possibly influencing results. Both of these studies show 
that TENS therapy is more effective in reducing development of PHN compared to antivirals, yet 
they do not comment on drug compliance. Some of the antivirals used are dosed 3-5 times per 
day, which could easily have led to missed doses and affected outcomes. 
Harmful side effects and adverse events due to TENS therapy have not been reported; the 
only contraindications to its use are implanted pacemakers and malignant skin lesions5,10. The 
studies in this systematic review reported no adverse events due to TENS therapy and no 
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significant difference between secondary bacterial infections caused by HZ vesicles in treatment 
or control groups4,5. 
CONCLUSION 
 TENS therapy is safe, inexpensive, and easy for patients to use, leading to its growing 
popularity in treating many acute and chronic pain conditions. The studies analyzed in this 
systematic review provide evidence suggesting TENS therapy is safe and effective in treating 
and preventing PHN. TENS therapy alone has been shown to decrease the incidence of PHN, but 
the mechanism behind this is unclear4,5,10. It is also unclear why the use of TENS therapy in 
combination with antivirals does not decrease the incidence of PHN. Both of these are areas of 
further research that could be investigated as TENS therapy becomes more commonly used. 
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